1) As my previous posts on this board will indicate, I am not a fan of Peter Traber. But the fact is that Traber did NOT join GALT until about a year AFTER that Feuerstein bash you posted. And as to Traber's questionable "track record", you must be talking about his time with that well known "P&D" Glaxosmithcline, where he served as Senior VP of Clinical Development and Chief Medical Officer. Or maybe you are talking about that other well "P&D" called the University of Pennsylvania Health System where he served as CEO. 2) That Feuerstein bash article you linked is from April of 2010 and yet you claim that "nothing real has changed" in five years? How about the name of the company in 2011? How about hiring Traber as the new CEO in 2011? How about the new focus on Fibrosis as the target for treatment? How about the completion of a successful Phase 1? How about the pending start of three separate Phase 2 trials?
If you have legitimate criticism of what the company is doing today, I am interested in hearing it. If all you have is 5 year old warmed over bashing from Feuerstein, you are wasting your time.